GSK 3903371
Alternative Names: BOS-371; GSK-3903371Latest Information Update: 03 Jul 2023
At a glance
- Originator GlaxoSmithKline
- Developer Boston Pharmaceuticals; GSK
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Interleukin-1 receptor accessory protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia
- Preclinical Cancer
Most Recent Events
- 03 Jul 2023 Phase-I clinical trials in Acute myeloid leukaemia in United Kingdom (Parenteral)
- 02 Jun 2023 Pharmacodynamics data from preclinical studies in Acute myeloid leukemia presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 18 Mar 2021 GlaxoSmithKline signs license and option agreement with Boston Pharmaceuticals for GSK 3903371